A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

NCT05085444 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Scleroderma
Autoimmune Diseases

Interventions

BIOLOGICAL: Assigned Interventions CD19/BCMA CAR T-cells

Sponsor

Zhejiang University

Collaborators

[object Object]